Skip to main content
SpringerLink
Log in
Book cover

Kompendium der Psychiatrischen Pharmakotherapie pp 661–743Cite as

Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten

  • Chapter

Zusammenfassung

In diesem Kapitel werden die Suchtmittel mit ihren Substanzcharakteristika, Entzugssyndromen, Entwöhnungsmaßnahmen und ihrer Intoxikationssymptomatik bzw. -therapie im Hinblick auf die verschiedenen spezifischen klinischen Syndrome der Suchtkrankheiten behandelt (7.1.2, Tab. 7.1). Die Gliederung erfolgt nicht nach Medikamentengruppen, sondern nach Suchtmitteln. Aufgrund der Neugruppierung im DSM-5, das erstmals das »pathologische Spielen« dem Kapitel der Suchterkrankungen (substance-related and addictive disorders) zuordnet, werden Substanzen, die zu dessen Behandlung geeignet sind, ebenfalls hier vorgestellt. Eine weitere Neuerung des DSM-5 sieht vor, dass stoffgebundene Suchterkrankungen nicht länger kategorial in Substanzmissbrauch und Substanzabhängigkeit getrennt werden, sondern Substanzgebrauchsstörungen (substance use disorders) nun in ihrer Ausprägung dimensional in »leicht«, »moderat« und »schwer« voneinander unterschieden werden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Anthenelli RM, Morris C, Ramey TS et al (2013) Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 159(6): 390–400

    Google Scholar 

  • Brown RM, Kupchik YM, Kalivas PW (2013) The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy. JAMA Psychiatry 70(9): 895

    Google Scholar 

  • Butelman ER, Yuferov V, Kreek MJ (2012) κ-Opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35(10): 587–796

    Google Scholar 

  • Foa EB, Yusko DA, McLean CP et al (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: A randomized clinical trial. JAMA 310: 488

    Google Scholar 

  • Grant JE, Odlaug BL, Chamberlain SR et al (2014) A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry 75(1): 39–45

    Google Scholar 

  • Grosshans M, Lemenager T, Vollmert C et al (2013) Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 69(12): 2021–2025

    Google Scholar 

  • Heinzerling KG, Swanson AN, Hall TM et al (2014) Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 109(11): 1878–1886

    Google Scholar 

  • Hohmann N, Mikus G, Czock D (2014) Wirkungen und Risiken neuartiger psychoaktiver Substanzen. Dt Ärztebl 9: 139–147

    Google Scholar 

  • Kampman KM, Pettinati HM, Lynch KG et al (2013) A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 133(1): 94–99

    Google Scholar 

  • Kishi T, Sevy S, Chekuri R, Correll CU (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. Clin Psychiatry 74(7): e642-54

    Google Scholar 

  • Levin FR, Mariani J, Brooks DJ et al (2013) A randomized double-blind, placebo controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108(6): 1084–1094

    Google Scholar 

  • Mann K, Fauth-Bühler M, Seiferth N, Heinz A; Expertengruppe Verhaltenssüchte der DGPPN (2013) Konzept der Verhaltenssüchte und Grenzen des Suchtbegriffs. Nervenarzt 84(5): 548–556

    Google Scholar 

  • Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109(40): E2657–664

    Google Scholar 

  • Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370(9584): 319–328

    Google Scholar 

  • Nowak D, Jörres RA, Rüther T (2014) E-cigarettes-prevention, pulmonary health, and addiction. Dtsch Arztebl Int 111(20): 349–355

    Google Scholar 

  • Rose JE, Behm FM (2014) Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 171(11): 1199–1205

    Google Scholar 

  • Sigmon SC, Dunn KE, Saulsgiver K et al (2013) A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70(12): 1347–1354

    Google Scholar 

  • Soyka M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 17(4): 619–626

    Google Scholar 

  • Stapleton J, West R, Hajek P et al (2013) Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 108(12): 2193–2201

    Google Scholar 

  • Sullivan JT, Sykora K, Schneiderman J et al (1999) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 84(11): 1353–1357

    Google Scholar 

  • Tiihonen J, Krupitsky E, Verbitskaya E et al (2012) Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 169(5): 531–536

    Google Scholar 

  • Verthein U, Beck T, Haasen C, Reimer J (2015) Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res 21(2): 97–104

    Google Scholar 

  • Yücel M, Lorenzetti V, Suo C et al (2016) Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry 12(6): e710

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mannheim

    Prof. Dr. med. F. Kiefer

  2. Mainz

    Prof. Dr. med. O. Benkert

Authors
  1. Prof. Dr. med. F. Kiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mainz

    Otto Benkert

  2. München

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kiefer, F., Benkert, O. (2017). Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50333-1_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50332-4

  • Online ISBN: 978-3-662-50333-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation